Excision of mutagenic replication-blocking lesions suppresses cancer but promotes cytotoxicity and lethality in nitrosamine-exposed mice
Author(s)
Kay, Jennifer E; Corrigan, Joshua J; Armijo, Amanda L; Nazari, Ilana S; Kohale, Ishwar N; Torous, Dorothea K; Avlasevich, Svetlana L; Croy, Robert G; Wadduwage, Dushan N; Carrasco, Sebastian E; Dertinger, Stephen D; White, Forest M; Essigmann, John M; Samson, Leona D; Engelward, Bevin P; ... Show more Show less
DownloadPublished version (2.461Mb)
Publisher with Creative Commons License
Publisher with Creative Commons License
Creative Commons Attribution
Terms of use
Metadata
Show full item recordAbstract
N-Nitrosodimethylamine (NDMA) is a DNA-methylating agent that has been discovered to contaminate water, food, and drugs. The alkyladenine DNA glycosylase (AAG) removes methylated bases to initiate the base excision repair (BER) pathway. To understand how gene-environment interactions impact disease susceptibility, we study Aag-knockout (Aag-/-) and Aag-overexpressing mice that harbor increased levels of either replication-blocking lesions (3-methyladenine [3MeA]) or strand breaks (BER intermediates), respectively. Remarkably, the disease outcome switches from cancer to lethality simply by changing AAG levels. To understand the underlying basis for this observation, we integrate a suite of molecular, cellular, and physiological analyses. We find that unrepaired 3MeA is somewhat toxic, but highly mutagenic (promoting cancer), whereas excess strand breaks are poorly mutagenic and highly toxic (suppressing cancer and promoting lethality). We demonstrate that the levels of a single DNA repair protein tip the balance between blocks and breaks and thus dictate the disease consequences of DNA damage.
Date issued
2021-03Department
Massachusetts Institute of Technology. Department of Biological Engineering; Massachusetts Institute of Technology. Center for Environmental Health Sciences; Massachusetts Institute of Technology. Division of Comparative Medicine; Koch Institute for Integrative Cancer Research at MIT; Center for Precision Cancer Medicine; Massachusetts Institute of Technology. Department of Chemistry; Massachusetts Institute of Technology. Department of BiologyJournal
Cell Reports
Publisher
Elsevier BV
ISSN
2211-1247